Patients with stable but lower renal function are not able to take part in early clinical trials based on the current inclusion criteria. Our aim is to provide the evidence to challenge the criteria to see if intensive home monitoring combined with a clinical algorithm can extend both monitoring and trial participation for patients.

Laura Hutchinson, Business Analyst, gave a poster presentation on ‘closer monitoring of renal function in early phase trials’ at the PRISME Forum (Pharmaceutical R&D Information Systems Management Executive) 2018 Spring technical meeting on Artificial Intelligence in Healthcare. This across pharma collaboration brought together R&D leaders and technology experts to look at the application of AI and machine learning in drug discovery and clinical development.